Volume 15, Number 1—January 2009
Vertical Transmission of Pneumocystis jirovecii in Humans
To the Editor: Currently, animal and human studies favor an airborne transmission pattern for Pneumocystis pneumonia (1). However, the early age of acquisition of Pneumocystis spp. in different mammals, including humans, warrants study of vertical/transplacental transmission as an additional route of transmission of this stenoxenic microorganism.
Available studies on transplacental transmission of Pneumocystis spp. suggest that it varies among mammal species on the basis of the type of placenta (2). Transplacental transmission of Pneumocystis spp. has been demonstrated in rabbits (2,3), but it seems not to occur in rats and mice that have severe combined immunodeficiency (1). In humans, transplacental transmission was first suggested by a few reports of Pneumocystis pneumonia in neonates published before the AIDS epidemic (4). Recently, a controversial case of vertical transmission of P. jirovecii was reported: an infection in the lungs of a fetus of an HIV-positive mother with Pneumocystis pneumonia (5). However, the study did not identify the organisms as Pneumocystis spp., and a subsequent fluorescein-labeled monoclonal antibody test yielded negative results (6).
The present study was conducted to evaluate transplacental transmission of P. jirovecii by molecular techniques. Placentas and lung tissues of aborted fetuses from immunocompetent women who had miscarriages were studied. To enhance specificity of the study, we used 2 genetic loci in Pneumocystis spp. DNA: the mitochondrial large subunit rRNA (mtLSU-rRNA) gene and the gene encoding for dihydropteroate synthase (DHPS). We analyzed 40 paraffin-embedded tissue blocks from the placentas and lungs of 20 fetuses at 28 ± 8 weeks of gestation. The study was reviewed and approved by the ethical committee of University Hospital, Seville, Spain.
DNA was extracted from a mixture of five 10-μm sections of each tissue block. Histologic sections were processed by using xylene and ethanol for paraffin removal and were then rehydrated. DNA was extracted by using the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions.
DNA amplification at the mtLSU-rRNA locus was conducted by using nested PCR as described (7). Samples identified as positive by this PCR were amplified by using primers DHPS-3 and DHPS-4 to detect the DHPS gene (7). To prevent false-positive results caused by contamination, pipettes with filters were used at all stages. DNA extraction, preparation of the reaction mixture, PCR amplification, and detection were conducted in different areas under a laminar flow hood. Positive and negative controls were included in each reaction. All experiments were repeated at least twice.
P. jirovecii genotypes can be characterized by identifying polymorphisms at the mtLSU-rRNA locus (positions 85 and 248) and at the DHPS locus (positions 55 and 57). Amplicons from all samples that yielded positive PCR results for the 2 loci were sequenced directly from both ends by using a model ABI 377 automated sequencer and an ABI prism Dye Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s instructions. The derived mtLSU-rRNA and DHPS gene sequences were compared with sequences available in databases by using the National Center for Biotechnology Information (Bethesda, MD, USA) BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
The mtLSU-rRNA fragment was amplified from 11 lung and 8 placenta samples. Simultaneous DNA amplification of 2 loci of P. jirovecii was observed in lung tissue samples from 7 (35%) of 20 fetuses and from 1 (5%) of 20 placenta samples. Sequencing of the mtLSU-rRNA gene showed 3 polymorphisms, and DHPS gene analysis showed only wild-type genotype in all samples (Table).
Our results provide molecular evidence of P. jirovecii transplacental transmission in humans. No available data on the development of Pneumocystis organisms in female genital organs was provided (8). In contrast, morphologic and molecular evidence of hematogenous dissemination of P. jirovecii from infected lungs has been provided by many authors (8). Pneumocystis DNA has been documented in blood or amniotic fluid samples from pregnant rabbit does (3), in which transplacental transmission of Pneumocystis spp. occurred. In humans, P. jirovecii colonization was observed in 5 (15.5%) of 33 pregnant women in their third trimester (9). These data suggest that physiologic immunodepression associated with pregnancy may favor Pneumocystis spp. colonization and mother-to-fetus transmission of the fungus by the hematogenous route. The transplacental route could enhance transmission of P. jirovecii independent of environmental hazards.
Isolation of pathogens from an aborted fetus does not necessarily mean that they have caused the death of the fetus because many agents appear to pass through the fetal-placental unit and cause little damage. However, fungal infection is a major worldwide cause of abortion in cattle (10), and the surprising high prevalence of P. jirovecii infection found in dead fetuses in our study emphasizes the need to study the possible role of this fungal organism in human abortion.
Our findings could be of potential clinical importance and could open a new field of research, which should be explored. Further research should assess the scope of the problem and design rational preventive strategies, if necessary.
This study is part of the project “Pneumocystis Pathogenomics: Unravelling the Colonization-to-Disease Shift,” a Coordination Action supported by the European Commission (ERANET PathoGenoMics). This study was partially supported by the Spanish Ministry of Health (FIS 03/1743). M.A.M.-C. and C.d.l.H. were supported by the Spanish Ministry of Health (FIS CP-04/217 and FIS CM-04/146).
- Dei-Cas E. Pneumocystis infections: the iceberg? Med Mycol. 2000;38(Suppl.1):23–32.
- Sanchez CA, Chabé M, Aliouat el M, Durand-Joly I, Gantois N, Conseil V, et al. Exploring transplacental transmission of Pneumocystis oryctolagi in first-time pregnant and multiparous rabbit does. Med Mycol. 2007;45:701–7.
- Cere N, Drouet-Viard F, Dei-Cas E, Chanteloup N, Coudert P. In utero transmission of Pneumocystis carinii sp. f. oryctolagi. Parasite. 1997;4:325–30.
- Pavlica F. The first observation of congenital pneumocystic pneumonia in a fully developed stillborn child. Ann Paediatr. 1962;198:177–84.
- Mortier E, Pouchot J, Bossi P, Molinie V. Maternal-fetal transmission of Pneumocystis carinii in human immunodeficiency virus infection. N Engl J Med. 1995;332:825.
- Hughes WT. Pneumocystis in infants and children. N Engl J Med. 1995;333:320–1.
- Montes-Cano MA, de la Horra C, Martin-Juan J, Varela JM, Torronteras R, Respaldiza N, Pneumocystis jiroveci genotypes in the Spanish population. Clin Infect Dis. 2004;39:123–8.
- Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev. 1997;10:401–18.
- Vargas SL, Ponce CA, Sanchez CA, Ulloa AV, Bustamante R, Juarez G. Pregnancy and asymptomatic carriage of Pneumocystis jiroveci. Emerg Infect Dis. 2003;9:605–6.
- Kirkbride CA. Etiologic agents detected in a 10-year study of bovine abortions and stillbirths. J Vet Diagn Invest. 1992;4:175–80.
- Table. Pneumocystis jirovecii genotypes in samples identified as positive by nested PCR for 2 loci from fetal lung tissues and placenta samples
Suggested citation for this article: Montes-Cano MA, Chabe M, Fontillon-Alberdi M, de la Horra C, Respaldiza N, Medrano FJ, et al. Vertical transmission of Pneumocystis jirovecii in humans [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Jan [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/1/08-0242
Please use the form below to submit correspondence to the authors or contact them at the following address:
Marco A. Montes-Cano, Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Avda Manuel Siurot s/n, 41013 Seville, Spain;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: November 19, 2010
- Page last updated: November 19, 2010
- Page last reviewed: November 19, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)